Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.33 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5222033 | 1.00 | BRD4 (0.37) | BRD4ABCB1ADORA3ADORA2AAAK1 | |
| SCHEMBL5218655 | 0.89 | BRD4 (0.37) | BRD4ABCB1ADORA3ADORA2AAAK1 | |
| SCHEMBL5218644 | 0.89 | BRD4 (0.37) | BRD4ABCB1ADORA3ADORA2AAAK1 | |
| SCHEMBL5224835 | 0.84 | AAK1 (0.38) | BRD4ABCB1ADORA3ADORA2AAAK1 | |
| SCHEMBL5224830 | 0.84 | AAK1 (0.38) | BRD4ABCB1ADORA3ADORA2AAAK1 | |
| SCHEMBL5223751 | 0.83 | BRD4 (0.37) | BRD4ABCB1ADORA3ADORA2AAAK1 | |
| SCHEMBL5223742 | 0.83 | BRD4 (0.37) | BRD4ABCB1ADORA3ADORA2AAAK1 | |
| SCHEMBL5222990 | 0.83 | ADORA3 (0.38) | BRD4ABCB1ADORA3ADORA2AAAK1 | |
| SCHEMBL5217784 | 0.82 | ABCB1 (0.35) | BRD4ABCB1ADORA3ADORA2AAAK1 | |
| SCHEMBL5217792 | 0.82 | ABCB1 (0.35) | BRD4ABCB1ADORA3ADORA2AAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641796-B1 | 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | HOFFMANN LA ROCHE (CH) | 2007-06-06 | — | — | EP | disclosed |
| US-7208494-B2 | 5HT2c receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | disclosed |
| EP-1641796-A1 | 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-05 | — | — | EP | disclosed |
| US-20050026925-A1 | 5HT2c receptor agonists | HOFFMANN-LA ROCHE INC. | 2005-02-03 | — | — | US | disclosed |
| WO-2005000849-A1 | 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026925-A1 | 5HT2c receptor agonists | HTR2C, HTR2A, HTR5A | BRD4 1755/4885ABCB1 751/4885ADORA3 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.